OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).

OBM Neurobiology publishes research articles, technical reports and invited topical reviews. Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 7.6 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).

Current Issue: 2021  Archive: 2020 2019 2018 2017

Special Issue

Emerging Concepts in Nucleoside Analogs as Novel Chemotherapeutic Agents to Treat Cancer

Submission Deadline: July 31, 2022 (Open) Submit Now

Guest Editor

Anthony Berdis, PhD, Professor

Department of Chemistry, Cleveland State University, Cleveland, USA.

Website | E-Mail

Research Interests: DNA polymerases, nucleoside analogs, cancer chemotherapy, DNA damage, mutagenesis, drug resistance

About This Topic

A hallmark of most cancers is their hyperproliferative nature which is dependent uopn higher rates of DNA synthesis.  As such, a rational therapeutic strategy against cancer is the utilization of nucleoside analogs that can inhibit DNA replication to generate both cytostatic and cytotoxic effects.  In this Special Issue, we are pleased to have several experts provide seminal articles that describe biochemical and clinical applications of existing nucleoside analogs in addition to describing efforts to develop new analogs that have improved pharmacodynamic and pharmacokinetic properties.

Announcement
Newsletter

TOP